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Performance Deﬁciencies in the Treatment of ST-Elevation
Myocardial Infarction in Quebec: “Tis But a Part We See,
and Not a Whole”
Rabih R. Azar, MD, MPH, FACC,a Zena Kadri, MD,a and David D. Waters, MD, FACCb
aHotel Dieu de France Hospital and the St Joseph University School of Medicine, Beirut, Lebanon
bSan Francisco General Hospital and the University of California San Francisco, San Francisco, California, USA
See article by Lambert et al., pages 1325.e11e1325.e18 of this issue.In his Essay on Man published between 1732 and 1734,
Alexander Pope presented his views on the role of humans in
the universe and their relation with God. Pope pointed out
that with our limited mindset and limited intellectual capac-
ities, we are only able to see a part, but not the whole. He
concluded that humans have to rely on hope and faith, and
accept many assumptions, because the universe functions in a
rational way according to laws set by God.1
However, at least in science, Pope was not right; the part
that we see might be different from the whole and belief must
rely on evidence and not on faith. This is highlighted in this
issue of the Canadian Journal of Cardiology, where Lambert
and colleagues evaluated the outcome of 3731 patients with
ST-elevation myocardial infarction (STEMI) admitted to
> 80 acute care centres in the province of Quebec over two
6-month periods.2 Hospitals were classiﬁed into 4 types
according to the method of reperfusion that was practiced:
primary percutaneous coronary intervention (PPCI) centres
were those where on-site PPCI was the exclusive reperfusion
modality, ﬁbrinolysis centres were those where ﬁbrinolysis was
the exclusive reperfusion treatment, transfer PPCI centres
were those without on-site PPCI but where all patients were
transferred to a PPCI facility, and mixed centres were those
where STEMI patients were either treated with ﬁbrinolysis or
transferred to a PPCI centre.
The authors’ objectives were to evaluate the performance
of these hospitals in the management of STEMI. Although
older studies have focused on examining the outcome of pa-
tients who received reperfusion therapy, the authors elected to
evaluate the outcome of all STEMI patients, stratiﬁed ac-
cording to the receiving centre. This is important to ascertain,
because subgroup analysis might be misleading.3 A look at theReceived for publication April 5, 2016. Accepted April 6, 2016.
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the performance of the health care system. Several important
ﬁndings of this article are worth discussing.Outcome in the “Part” and the “Whole”
When analysis was performed in patients who received
reperfusion treatment, crude 30-day mortality did not differ
across the 4 types of centres. This might lead to the erroneous
conclusion that STEMI management is equivalent, irre-
spective of accessibility to PPCI and the type of reperfusion
treatment. However, when all patients with STEMI were
analyzed, outcome was signiﬁcantly different, with an adjusted
30-day mortality being 58% higher in mixed centres
compared with centres that provide PPCI. This was mainly
driven by a higher mortality rate in patients who did not
receive reperfusion therapy. Management of STEMI is thus,
not similar across all facilities and the implications in terms of
public health policy are different from those that could be
derived from the ﬁrst conclusion on the basis of subgroup
analysis of patients who received reperfusion therapy.
The authors were right in stressing the “importance of
examining all patients.” It is not uncommon in clinical studies
to exclude some categories of patients leading to a sample that
does not represent the true population, or to draw conclusions
on the basis of subgroup analysis, which might not reﬂect the
outcome in the whole population. A strong effort was recently
made by the research community to correct these problems.
The Consolidated Standards of Reporting Trials was devel-
oped to guide randomized clinical trials.4 Similarly, the
Strengthening the Reporting of Observational Studies in
Epidemiology statement was recently published to guide the
design and reporting of observational and case-control
studies.5 These guidelines put a particular emphasis on se-
lection of the study population, and recommend a clear
explanation on how the sample was chosen and the rationale
for the inclusion criteria. They also stress the importance of
analyzing all patients, explaining withdrawals, loss of follow-
up, incomplete data, and evaluation of confounders.ll rights reserved.
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conclusions as was shown by Lambert and colleagues in their
current report.2The Problem of Untreated Patients
Despite the well-established beneﬁt of early revasculariza-
tion in patients with STEMI, 21.8% of patients did not
receive a reperfusion treatment, with signiﬁcant variability
across centres, being highest in ﬁbrinolysis centres and lowest
in PPCI centres. Mortality among these patients was 3-4 times
higher than for patients who received reperfusion treatment
and accounted for the higher crude and adjusted mortality
rates in the mixed centres. In an article published by the same
authors,6 the most important predictors of nontreatment were
limited accessibility to PPCI, presence of left bundle branch
block, or an ambiguous electrocardiogram (ECG). In addi-
tion, the study raises the possibility of a referral bias in mixed
centres, where low-risk patients were referred for revasculari-
zation but high-risk patients, who theoretically should beneﬁt
the most from reperfusion therapy, were not. This hypothesis
should be addressed in a separate study because of its
important clinical implications.The Delay in Reperfusion Treatment
Reperfusion therapy was given outside the recommended
time window in most cases when it was used. In PPCI centres
only 35.4% of patients received it in a timely fashion, vs
11.9% in transfer centres and 1.2% in mixed centres. This is
much lower than in other developed countries. In the Global
Registry of Acute Coronary Events (GRACE) registry, 58% of
the patients with STEMI had PPCI within 90 minutes.7
Although the delay in transfer centres and mixed centres
can be expected, this should not occur in centres with on-site
PPCI capability. The causes of such delay should be investi-
gated in future studies. Contrary to PPCI, thrombolytic
therapy was given within the time window in 50% of patients
in ﬁbrinolysis and mixed centres. This could at least partially
explain the good results of ﬁbrinolysis centres despite the
lower rate of reperfusion treatment compared with PPCI
centres (70.2% vs 83.3%). The American College of Cardi-
ology guidelines for STEMI recommend ﬁbrinolysis in non-
PPCI-capable hospitals when it is anticipated that PPCI
cannot be performed within 120 minutes of ﬁrst medical
contact.8 Median delay was 149 minutes in mixed centres,
well above these guidelines.Limitations of the Current Study
The authors did not report on reinfarction, ejection frac-
tion at discharge, new-onset congestive heart failure, and
stroke rates. These factors are important to evaluate because
they affect long-term outcome. Preservation of left ventricular
function using early revascularization was associated with
improved 1-year survival despite similar 30-day mortality.9
Rates of reperfusion treatment and time to reperfusion were
different across the 4 groups, which might affect the amount
of myocardium being salvaged and consequently long-term
survival. Although not statistically signiﬁcant, adjusted mor-
talities were higher in ﬁbrinolysis (odds-ratio, 1.5) and transfer
centres (odds ratio, 1.3) compared with PPCI centres. It ispossible that a larger sample or a longer follow-up (more
events) might have made these differences statistically
signiﬁcant.Public Health Implications
This study has important clinical and public health im-
plications. As the authors mentioned, rather than increasing
the number of facilities with on-site PPCI, the functioning of
the health care system should be improved. Two major targets
for intervention are the number of patients who receive
reperfusion therapy and the delay of such therapy. Physicians
working in remote facilities should be educated to better
interpret ECGs and to refer patients with chest pain and
ambiguous ECG or left bundle branch block for emergent
coronary angiography. Transfer networks should be revised
and improved to facilitate and accelerate transfers. Mixed
centres where PPCI was almost always delayed and ﬁbrino-
lysis was given promptly could be transformed into ﬁbrino-
lysis centres. Because the authors hypothesized that patients
who were transferred were at lower risk, transfer conditions
should be studied to determine the safety of transfer of
“higher-risk” patients who otherwise would not receive
reperfusion therapy.
In conclusion, the current study shed important light on
the functioning of the health care system in the province of
Quebec. Although several questions remain unanswered, the
inclusion of more than 95% of STEMI patients and the
analysis of all of them allowed the authors to approach
more toward seeing the “whole.” Contrary to Alexander
Pope who concluded his Epistle II by “Whatever is, is
right,”1 Lambert et al. have shown that the management of
STEMI (whatever is), is not perfect. Their ﬁndings will be
very useful in improving the performance of the health care
system.2Disclosures
The authors have no conﬂicts of interest to disclose.
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